{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:07:23Z","timestamp":1791220043682,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000142","name":"Arthritis Society","doi-asserted-by":"publisher","award":["SOG-22-192"],"award-info":[{"award-number":["SOG-22-192"]}],"id":[{"id":"10.13039\/501100000142","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ero.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EULAR Rheumatology Open"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ero.2025.06.011","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T21:19:21Z","timestamp":1754687961000},"page":"182-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pregnancy outcomes of non-tumour necrosis factor inhibitor biologic disease-modifying antirheumatic drugs among individuals with autoimmune diseases: a scoping review and proposed framework for reporting outcomes"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7053-559X","authenticated-orcid":false,"given":"Vienna","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2185-3347","authenticated-orcid":false,"given":"Neda","family":"Amiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5030-9135","authenticated-orcid":false,"given":"Vicki","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5896-4852","authenticated-orcid":false,"given":"Ursula","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6284-938X","authenticated-orcid":false,"given":"Jacquelyn J.","family":"Cragg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1656-0371","authenticated-orcid":false,"given":"Laurie","family":"Proulx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2205-2683","authenticated-orcid":false,"given":"Mary A.","family":"De Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ero.2025.06.011_bib0001","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40273-014-0174-6","article-title":"The burden of disease in rheumatoid arthritis","volume":"32","author":"Uhlig","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.ero.2025.06.011_bib0002","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/art.21663","article-title":"Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis","volume":"54","author":"Chakravarty","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.ero.2025.06.011_bib0003","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/art.24462","article-title":"Biologic therapy and pregnancy outcomes in women with rheumatic diseases","volume":"61","author":"Vinet","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ero.2025.06.011_bib0004","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1196\/annals.1351.019","article-title":"Epidemiological aspects of rheumatoid arthritis: the sex ratio","volume":"1069","author":"Kvien","year":"2006","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"10.1016\/j.ero.2025.06.011_bib0005","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/rheumatology\/keab544","article-title":"Age at onset in axial spondyloarthritis around the world: data from the Assessment in SpondyloArthritis international Society Peripheral Involvement in Spondyloarthritis study","volume":"61","author":"Boel","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ero.2025.06.011_bib0006","first-page":"73","article-title":"Risk of pre-eclampsia and impact of disease activity and anti-rheumatic treatment in women with rheumatoid arthritis, axial spondylarthritis, and psoriatic arthritis: a collaborative matched cohort study from Sweden and Denmark [abstract]","author":"Secher","year":"2021","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.ero.2025.06.011_bib0007","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/acr.23730","article-title":"Factors associated with preterm delivery among women with rheumatoid arthritis and women with juvenile idiopathic arthritis","volume":"71","author":"Smith","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"10.1016\/j.ero.2025.06.011_bib0008","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00384-022-04185-9","article-title":"A national study of pregnancy-related maternal and fetal outcomes in women with inflammatory bowel disease","volume":"37","author":"Tarar","year":"2022","journal-title":"Int J Colorectal Dis"},{"issue":"4","key":"10.1016\/j.ero.2025.06.011_bib0009","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1080\/14767058.2018.1498835","article-title":"Pregnancy outcomes in women with rheumatoid arthritis: a retrospective population-based cohort study","volume":"33","author":"Aljary","year":"2020","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"8","key":"10.1016\/j.ero.2025.06.011_bib0010","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/ecco-jcc\/jjaa026","article-title":"Newborn congenital abnormalities and inflammatory bowel disease: unveiling an unexplored relationship","volume":"14","author":"Magro","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"5","key":"10.1016\/j.ero.2025.06.011_bib0011","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/ecco-jcc\/jjaa225","article-title":"The influence of disease activity on pregnancy outcomes in women with inflammatory bowel disease: a systematic review and meta-Analysis","volume":"15","author":"Kim","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"6","key":"10.1016\/j.ero.2025.06.011_bib0012","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","article-title":"Use of biologics in rheumatoid arthritis: current and emerging paradigms of care","volume":"33","author":"Curtis","year":"2011","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.ero.2025.06.011_bib0013","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3109\/09546634.2015.1054782","article-title":"Biologics and biosimilars","volume":"26","author":"Patel","year":"2015","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ero.2025.06.011_bib0014","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaut.2016.11.004","article-title":"Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-\u03b1 use in females with immune mediated diseases; a systematic review and meta-analysis","volume":"76","author":"Komaki","year":"2017","journal-title":"J Autoimmun"},{"issue":"8","key":"10.1016\/j.ero.2025.06.011_bib0015","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1093\/rheumatology\/keaa064","article-title":"Maternal and neonatal outcomes associated with biologic exposure before and during pregnancy in women with inflammatory systemic diseases: a systematic review and meta-analysis of observational studies","volume":"59","author":"Tsao","year":"2020","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.ero.2025.06.011_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.09.021","article-title":"Biologics for inflammatory bowel disease and their safety in pregnancy: a systematic review and meta-analysis","volume":"20","author":"Nielsen","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.ero.2025.06.011_bib0017","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1136\/annrheumdis-2024-eular.2854","article-title":"AB1439\u2005update of the eular points to consider for use of antirheumatic drugs in reproduction, pregnancy and lactation","volume":"83","author":"F\u00f6rger","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ero.2025.06.011_bib0018","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/acr.24130","article-title":"2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Care Res"},{"issue":"8","key":"10.1016\/j.ero.2025.06.011_bib0019","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/rheumatology\/ket409","article-title":"Biologic therapies and pregnancy: the story so far","volume":"53","author":"Hyrich","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.ero.2025.06.011_bib0020","series-title":"Joanna Briggs Institute reviewers\u2019 manual 2015: Methodology for JBI Scoping Reviews","author":"Institute","year":"2015"},{"issue":"1","key":"10.1016\/j.ero.2025.06.011_bib0021","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey","year":"2005","journal-title":"Int J Soc Res Methodol"},{"issue":"5","key":"10.1016\/j.ero.2025.06.011_bib0022","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/1759720X14551568","article-title":"Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to know","volume":"6","author":"Krause","year":"2014","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"10.1016\/j.ero.2025.06.011_bib0023","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s13643-021-01821-3","article-title":"Scoping reviews: reinforcing and advancing the methodology and application","volume":"10","author":"Peters","year":"2021","journal-title":"Syst Rev"},{"issue":"7","key":"10.1016\/j.ero.2025.06.011_bib0024","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ero.2025.06.011_bib0025","unstructured":"Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. Available from www.covidence.org"},{"issue":"6","key":"10.1016\/j.ero.2025.06.011_bib0026","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.3390\/cancers15061707","article-title":"Reproductive health outcomes among adolescent and young adult cancer patients: a systematic review and meta-analysis","volume":"15","author":"Oveisi","year":"2023","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.ero.2025.06.011_bib0027","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/acr.25502","article-title":"Pregnancy outcomes of targeted synthetic disease-modifying antirheumatic drugs among patients with autoimmune diseases: a scoping review","volume":"77","author":"Cheng","year":"2025","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"10.1016\/j.ero.2025.06.011_bib0028","doi-asserted-by":"crossref","first-page":"5378","DOI":"10.1111\/bcp.15471","article-title":"Reported congenital malformations after exposure to non-tumour necrosis factor inhibitor biologics: a retrospective comparative study in EudraVigilance","volume":"88","author":"Ghalandari","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ero.2025.06.011_bib0029","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40259-022-00564-4","article-title":"Fetal and neonatal adverse drug reactions associated with biologics taken during pregnancy by women with autoimmune diseases: insights from an analysis of the World Health Organization Pharmacovigilance Database (VigiBase(\u00ae))","volume":"37","author":"Dernoncourt","year":"2023","journal-title":"BioDrugs"},{"issue":"7","key":"10.1016\/j.ero.2025.06.011_bib0030","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000000186","article-title":"Exposure to vedolizumab in IBD pregnant women appears of low risk for mother and neonate: a first prospective comparison study","volume":"114","author":"Bar-Gil Shitrit","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.ero.2025.06.011_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(22)60251-8","article-title":"452: Paternal exposure to inflammatory bowel disease medications and neonatal outcomes","volume":"162","author":"Barber","year":"2022","journal-title":"Gastroenterology"},{"issue":"supplement_1","key":"10.1016\/j.ero.2025.06.011_bib0032","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjx180.406","article-title":"P279 Vedolizumab is safe for use in pregnant patients with IBD; report of our preliminary data","volume":"12","author":"Bar-Gil Shitrit","year":"2018","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.ero.2025.06.011_bib0033","doi-asserted-by":"crossref","first-page":"i508","DOI":"10.1093\/ecco-jcc\/jjac190.0508","article-title":"Pharmacokinetics of vedolizumab and ustekinumab in pregnant women with inflammatory bowel disease and their infants exposed in-utero","volume":"17","author":"Prentice","year":"2023","journal-title":"J Crohns Colitis. 2023"},{"issue":"11","key":"10.1016\/j.ero.2025.06.011_bib0034","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/jamapediatrics.2015.1982","article-title":"Inflammatory bowel disease in children and adolescents","volume":"169","author":"Rosen","year":"2015","journal-title":"JAMA Pediatr"},{"issue":"2","key":"10.1016\/j.ero.2025.06.011_bib0035","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1530\/ror.0.0040081","article-title":"Dynamics of immunoglobulins at the feto-maternal interface","volume":"4","author":"Saji","year":"1999","journal-title":"Rev Reprod"},{"issue":"3","key":"10.1016\/j.ero.2025.06.011_bib0036","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","article-title":"Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease","volume":"11","author":"Mahadevan","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.ero.2025.06.011_bib0037","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1055\/s-0035-1556745","article-title":"Identifying human teratogens: an update","volume":"4","author":"Alwan","year":"2015","journal-title":"J Pediatr Genet"},{"issue":"6","key":"10.1016\/j.ero.2025.06.011_bib0038","first-page":"976","article-title":"Risk of congenital anomalies in infants born to women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study","volume":"37","author":"Tsao","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ero.2025.06.011_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.621247","article-title":"Biologics during pregnancy and breastfeeding among women with rheumatic diseases: safety clinical evidence on the road","volume":"12","author":"Beltagy","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.ero.2025.06.011_bib0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/bjd.17086","article-title":"Ustekinumab exposure during conception and pregnancy in patients with chronic plaque psoriasis: a case series of 10 pregnancies","volume":"180","author":"Watson","year":"2019","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.ero.2025.06.011_bib0041","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.semarthrit.2021.06.005","article-title":"Pregnancy outcomes in patients treated with belimumab: report from real-world experience","volume":"51","author":"Kao","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.ero.2025.06.011_bib0042","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1191\/0962280206sm433oa","article-title":"Methodologic issues in the design and analysis of epidemiologic studies of pregnancy outcome","volume":"15","author":"Savitz","year":"2006","journal-title":"Stat Methods Med Res"},{"issue":"suppl 9","key":"10.1016\/j.ero.2025.06.011_bib0043","article-title":"Pregnancy outcomes of biosimilars and non-TNF inhibitor biologic disease-modifying antirheumatic drugs: a scoping review [abstract]","volume":"76","author":"Cheng","year":"2024","journal-title":"Arthritis Rheumatol"}],"container-title":["EULAR Rheumatology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708125000540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708125000540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T15:48:54Z","timestamp":1763308134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050708125000540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S3050708125000540"],"URL":"https:\/\/doi.org\/10.1016\/j.ero.2025.06.011","relation":{},"ISSN":["3050-7081"],"issn-type":[{"value":"3050-7081","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pregnancy outcomes of non-tumour necrosis factor inhibitor biologic disease-modifying antirheumatic drugs among individuals with autoimmune diseases: a scoping review and proposed framework for reporting outcomes","name":"articletitle","label":"Article Title"},{"value":"EULAR Rheumatology Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2025.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}